InnoPharmax
InnoPharmax works on 1 rare disease tracked on Trial Friend, including Cholangiocarcinoma, with 2 recruiting clinical trials.
InnoPharmax is a Taipei, Taiwan-based pharmaceutical company working on a deceptively practical idea: taking chemotherapy drugs that have only ever existed as hospital IV infusions and turning them into capsules a patient can swallow at home. Its lead program, D07001, is an oral softgel formulation of gemcitabine, a chemotherapy backbone that has been given intravenously for roughly 3 decades.
D07001 is more than a convenience play. The capsule uses metronomic dosing, meaning low doses taken frequently rather than the large periodic infusions of traditional chemotherapy. That schedule is designed to keep killing tumor cells while also modulating the immune response and cutting off the blood vessel growth tumors depend on, with less of the systemic toxicity that makes conventional gemcitabine hard to tolerate. For bile duct cancer (cholangiocarcinoma), an aggressive rare cancer where patients often carry a double burden of disease symptoms and chemotherapy side effects, an oral low-toxicity option would represent a genuine shift in how treatment feels day to day.
The company's pivotal Phase 3 study of D07001 (NCT06622057) began in June 2026, with sites in the United States and Taiwan. It is a double-blind, randomized trial in about 240 adults with advanced biliary tract cancer, including bile duct cancer, after gemcitabine plus cisplatin and then FOLFOX or irinotecan chemotherapy stopped working or caused side effects they could not tolerate, or who declined FOLFOX. Everyone takes capecitabine pills, and each person also gets 1 of 2 D07001 doses or a placebo; the main goal is longer survival. A separate open-label Phase 2/3 study in Taiwan is testing D07001 with capecitabine or TS-1, and Phase 1 results in advanced solid tumors were published in The Oncologist in 2025. The company has also said it plans to pursue a Phase 3 program in pancreatic cancer.
Like many mid-sized Taiwanese pharma companies, InnoPharmax funds its research partly through a specialty and generics business: it won approval for a generic version of sapropterin (the phenylketonuria treatment better known as Kuvan) and, with partner Shandong New Era Pharmaceutical, brought a gadopentetate imaging agent through China's NMPA. A late-2024 capital raise of NT$225 million was earmarked specifically to push D07001 through the clinic under CEO Wei-Hua Hao.
InnoPharmax Drug Pipeline
InnoPharmax has 2 active clinical trials across 1 development stage, with 2 currently recruiting participants. Clinical trials advance through phases: Phase 1 tests safety in a small group, Phase 2 evaluates effectiveness and side effects, Phase 3 confirms benefit in a larger population, and Phase 4 monitors long-term safety after FDA approval.
Note: This pipeline counts the active and recruiting trials listed on this page, from ClinicalTrials.gov. For companies that work outside rare disease, we list only trials for rare diseases we track, so the company's full pipeline may be larger.
InnoPharmax Clinical Trials (2)
Active and recruiting clinical trials sponsored by InnoPharmax, sourced live from ClinicalTrials.gov. Each trial card shows the study phase, current recruitment status, conditions under investigation, study locations, eligibility criteria, and a direct link to the full ClinicalTrials.gov record. You can also download a one-page PDF summary to share with your doctor.
Note: Recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator.
Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only InnoPharmax. Unsubscribe anytime.
You'll get new recruiting trials, changes to trials, FDA decisions and condition news for Cholangiocarcinoma. Turn any of these off from the link in every email.
FDA-Approved Drugs
InnoPharmax Trial Locations
InnoPharmax clinical trials are running at 9 sites in 2 countries. Click any country to drill down by state, city, and individual research facility. Proximity to a trial site is one of the most important factors in deciding whether to participate.
Rare Disease Focus Areas (1)
Diseases targeted by InnoPharmax's clinical trial and drug development programs
Patient Resources
Organizations and resources related to InnoPharmax's rare disease focus areas
Frequently Asked Questions About InnoPharmax
Common questions about InnoPharmax's rare disease programs, clinical trials, and treatments.